ClinicalTrials.Veeva

Menu
T

Texas Retina Associates | Plano, TX

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

KSI-301
Aflibercept
Tarcocimab

Parent organization

This site is a part of Texas Retina Associates

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

1 of 4 total trials
Locations recently updated

A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer Compared With Sham Treatment in Participants With Moderately Severe to Severe Non-proliferative Diabetic Retinopathy (NPDR) (GLOW2)

This study will demonstrate that tarcocimab 5 mg is superior to sham treatment in participants with moderately severe to severe NPDR.

Enrolling
Non-proliferative Diabetic Retinopathy
Drug: Tarcocimab
Other: Sham injection

Trial sponsors

Kodiak Sciences logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems